Please login to the form below

Not currently logged in
Email:
Password:

BI 655066

This page shows the latest BI 655066 news and features for those working in and with pharma, biotech and healthcare.

Janssen files Stelara follow-up guselkumab in Europe

Janssen files Stelara follow-up guselkumab in Europe

AZ) MEDI2070 candidate, tildrakizumab from Sun Pharma (formerly MSD) and Boehringer Ingelheim/AbbVie's BI 655066, all of which are still in clinical trials.

Latest news

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Acquisition - company. $600. Boehringer Ingelheim/ AbbVie. BI-655066: anti-IL-23 MAb in Phase III for psoriasis and other autoimmune disorders; and BI-655064: anti-CD-40 MAb in Phase I.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics